PeptidePedia The community reference

Contributions of Chromatokid

User contributions·266 logged edits·page 2 of 3

Contributions by Chromatokid, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 41,208 edits includes activity predating the current log.

  1. 10:20, 8 Dec 2025 (diff | hist) Talk:Temperature excursion 1,518 +309 /* Is a community-reported stability observation usable evidence at all? */ reply
  2. 12:55, 4 Dec 2025 (diff | hist) Talk:Peptide stability table 748 +339 /* Should extrapolated rows be in the table at all? */ reply
  3. 06:08, 29 Nov 2025 (diff | hist) Glucagon-like peptide-1 12,294 ±0 expand §Therapeutic exploitation
  4. 23:01, 27 Nov 2025 (diff | hist) WuXi TIDES 16,434 +220 expand §External links
  5. 19:19, 21 Nov 2025 (diff | hist) GenScript Peptides 10,236 +556 add the note that this wiki publishes no score and no league table
  6. 07:55, 20 Nov 2025 (diff | hist) Talk:Glucagon-like peptide-1 885 +147 /* Is the "50–75% degraded before leaving the gut" figure attributable? */ reply
  7. 04:30, 16 Nov 2025 (diff | hist) Purity claim inflation 5,660 ±0 add the note on how to request a batch record rather than a certificate
  8. 15:56, 12 Nov 2025 (diff | hist) ChinaPeptides 14,759 ±0 m ce per PP:MOS
  9. 12:24, 11 Nov 2025 (diff | hist) Peptide stability table 6,798 ±0 close an unbalanced quotation mark
  10. 08:02, 4 Nov 2025 (diff | hist) Syringe dead space 10,426 +1,422 clarify that the figure is per dose, not per vial
  11. 10:43, 2 Nov 2025 (diff | hist) Shenzhen Hybio Pharmaceutical 9,295 ±0 add the note that self-published material is usable only for what it states about itself
  12. 03:32, 2 Nov 2025 (diff | hist) Oral semaglutide 4,582 ±0 expand §Analytical and handling notes
  13. 08:30, 30 Oct 2025 (diff | hist) Sarcopenia 4,491 +252 m expand §Relevance to weight reduction
  14. 02:45, 29 Oct 2025 (diff | hist) Purity claim inflation 5,660 ±0 split §What a report shows from §What it does not
  15. 04:21, 27 Oct 2025 (diff | hist) Proglucagon 6,709 ±0 add the counter-regulatory glucagon point, sourced
  16. 00:29, 22 Oct 2025 (diff | hist) Xi'an Mokemei Biotechnology 12,005 +543 m expand §Regulatory position and legal status
  17. 13:59, 21 Oct 2025 (diff | hist) GLP-1 receptor agonist 11,264 +116 m de-orphan
  18. 19:33, 17 Oct 2025 (diff | hist) Shanghai Wibson Biotechnology 13,616 +1,089 fix hyphenation per PP:MOS
  19. 15:57, 15 Oct 2025 (diff | hist) Multi-dose vial 21,761 +276 the rounding in the table lost a decimal place that matters at low doses
  20. 19:18, 9 Oct 2025 (diff | hist) Insulin syringe 4,944 ±0 m correct the label on the second column — that is volume, not mass
  21. 11:49, 8 Oct 2025 (diff | hist) Hubei Jianxiang Bioscience 10,014 +321 state the city and province of the registered address
  22. 08:34, 6 Oct 2025 (diff | hist) GLP-1 receptor 7,570 ±0 add the species in which the knockout work was done
  23. 07:59, 1 Oct 2025 (diff | hist) Wuhan Wansheng Biotechnology 15,629 +226 add the transit window each regional warehouse serves
  24. 16:46, 26 Sep 2025 (diff | hist) Receptor bias 4,477 ±0 correct the second-messenger pathway named in the lead
  25. 11:18, 24 Sep 2025 (diff | hist) Shenzhen Hybio Pharmaceutical 7,111 +2,345 add the storage and handling guidance the organisation publishes
  26. 16:35, 17 Sep 2025 (diff | hist) Talk:WuXi TIDES 748 +294 /* Where should the ordering facts sit? */ reply
  27. 05:31, 15 Sep 2025 (diff | hist) Syringe dead space 4,115 +1,517 rm the brand-specific instruction; it is not general
  28. 22:41, 13 Sep 2025 (diff | hist) Analytical method validation 5,342 ±0 de-orphan
  29. 16:38, 13 Sep 2025 (diff | hist) GLP-1 receptor 7,570 ±0 m expand §Structure and ligand engagement
  30. 02:15, 12 Sep 2025 (diff | hist) Syringe dead space 2,598 ±0 expand §Terminology and reporting problems
  31. 10:49, 8 Sep 2025 (diff | hist) Patent expiry and biosimilars 4,183 ±0 m state that the position differs between jurisdictions and give two examples
  32. 23:07, 7 Sep 2025 (diff | hist) Tirzepatide 8,037 ±0 correct the dose ladder — the maintenance dose is not the maximum dose
  33. 16:51, 31 Aug 2025 (diff | hist) Fasting insulin 4,198 ±0 add the interference the assay is known to be subject to
  34. 23:19, 28 Aug 2025 (diff | hist) Mass spectrometry 5,612 ±0 add the ionisation mode to the mass-spectrometry description
  35. 16:21, 22 Aug 2025 (diff | hist) Beta cell function 6,096 +345 add a figure for the secretion time course and caption it
  36. 23:37, 20 Aug 2025 (diff | hist) Lyophilisation 26,375 +1,596 add the reconstitution-stability sentence with its storage condition
  37. 14:07, 19 Aug 2025 (diff | hist) Talk:Qingdao Saber Technology Pharmaceutical 748 +324 /* Appearance and purity are separate observations */ reply
  38. 01:26, 14 Aug 2025 (diff | hist) Certificate of analysis 9,814 +365 clarify that agreement between certificate and report is a weak finding
  39. 22:36, 13 Aug 2025 (diff | hist) Hubei Jianxiang Bioscience 8,536 +489 rm the price; supplier articles carry no price per PP:VN
  40. 19:22, 11 Aug 2025 (diff | hist) Missed dose 5,277 +246 clarify that the figure is per dose, not per vial
  41. 07:59, 9 Aug 2025 (diff | hist) Purity claim inflation 5,442 ±0 state that the report identifies the sample, not the shipment
  42. 02:44, 3 Aug 2025 (diff | hist) Peptide 6,609 ±0 m rm a duplicated category
  43. 13:41, 24 Jul 2025 (diff | hist) Janoshik Analytical 5,235 ±0 m copyedit
  44. 00:16, 21 Jul 2025 (diff | hist) Sigma-Aldrich (Shanghai) Trading 10,301 +899 m add the minimum order quantity for custom synthesis
  45. 13:58, 20 Jul 2025 (diff | hist) Talk:Shanghai ERP Biotechnology 611 +168 /* Verifiability when the name is unsearchable */ reply
  46. 04:37, 18 Jul 2025 (diff | hist) Contract development and manufacturing organisation 4,794 +554 expand §Consequences for reading documentation
  47. 14:51, 16 Jul 2025 (diff | hist) Residual solvent 4,819 +658 split §Principle from §Practical limitations
  48. 19:33, 14 Jul 2025 (diff | hist) HOMA-IR 4,218 ±0 copyedit
  49. 05:23, 14 Jul 2025 (diff | hist) MOTS-c 4,435 +839 state the research-use-only status in the lead, not only in the footer
  50. 14:50, 13 Jul 2025 (diff | hist) Retatrutide 7,261 +1,367 rm the comparison to a compound with no published head-to-head data
  51. 18:36, 11 Jul 2025 (diff | hist) Peptide 6,609 ±0 expand §Nomenclature and notation
  52. 01:51, 11 Jul 2025 (diff | hist) Peptide harm reduction 4,585 +610 m add the cross-link to the insurance article
  53. 11:46, 10 Jul 2025 (diff | hist) SURMOUNT trial programme 4,572 ±0 m add the trial registration identifier
  54. 02:38, 10 Jul 2025 (diff | hist) Solid-phase peptide synthesis 5,359 ±0 m fix the anchor on an internal link
  55. 16:36, 8 Jul 2025 (diff | hist) GL Biochem (Shanghai) 14,542 +226 attribute the capability claim to the organisation's own material
  56. 12:37, 6 Jul 2025 (diff | hist) Hunan Aslsen Technology 10,989 +335 m state the city and province of the registered address
  57. 05:21, 2 Jul 2025 (diff | hist) Sterility testing 4,438 +775 close an unbalanced quotation mark
  58. 12:41, 20 Jun 2025 (diff | hist) Patent expiry and biosimilars 3,580 ±0 clarify the difference between a marketing authorisation and a registration
  59. 19:26, 15 Jun 2025 (diff | hist) Temperature excursion 10,117 +652 add the cross-link to the temperature-excursion article
  60. 00:17, 14 Jun 2025 (diff | hist) Grey market 3,461 ±0 correct the transit-time figure — the source gives a median, not a maximum
  61. 01:32, 6 Jun 2025 (diff | hist) Temperature excursion 9,465 +180 add category for logistics
  62. 04:27, 3 Jun 2025 (diff | hist) Growth hormone secretagogue 3,620 ±0 state which receptor subtype the binding data refers to
  63. 12:39, 25 May 2025 (diff | hist) Sarcopenia 3,762 +49 give the coefficient of variation with the level it was measured at
  64. 00:13, 19 May 2025 (diff | hist) Hubei Jianxiang Bioscience 5,320 +491 m space between number and unit per PP:MOS
  65. 09:03, 15 May 2025 (diff | hist) Talk:Reconstitution calculator 959 +209 /* Should the default vial mass be the gross or net figure? */ reply
  66. 18:42, 10 May 2025 (diff | hist) Resin cleavage 3,304 +27 rm the blanket claim that excursions are harmless
  67. 02:01, 8 May 2025 (diff | hist) Beta cell function 4,938 +22 add the cleavage site by residue number
  68. 06:21, 27 Apr 2025 (diff | hist) Lyophilisation 20,900 +873 add the crimp-seal step to the fill-and-finish description
  69. 01:12, 26 Apr 2025 (diff | hist) Third-party testing 5,770 ±0 m fix a broken wikilink
  70. 23:11, 23 Apr 2025 (diff | hist) Contraindications of incretin therapy 4,296 ±0 m add the medical-disclaimer cross-link
  71. 20:42, 20 Apr 2025 (diff | hist) Bacterial endotoxin test 4,398 ±0 add the sample preparation, since the result depends on it
  72. 08:46, 20 Apr 2025 (diff | hist) Cost per milligram 3,122 +121 add the note that prices below the list price are not evidence of a counterfeit
  73. 19:20, 6 Apr 2025 (diff | hist) Gastric emptying 4,636 ±0 m add the reference range with the assay it was established on
  74. 20:29, 4 Apr 2025 (diff | hist) Repackaging 3,958 ±0 m add the collapse-temperature point, sourced
  75. 05:38, 2 Apr 2025 (diff | hist) Global access disparity 2,619 ±0 attribute the survey figure to the survey and give its sample size
  76. 14:33, 1 Apr 2025 (diff | hist) International nonproprietary name 3,145 ±0 split overlong sentence
  77. 01:54, 30 Mar 2025 (diff | hist) Baseline laboratory panel 3,039 ±0 m split the analytical performance from the clinical interpretation
  78. 13:23, 25 Mar 2025 (diff | hist) Orforglipron 4,165 +109 expand §Reported clinical findings
  79. 19:15, 20 Mar 2025 (diff | hist) Enteroendocrine L cell 4,619 ±0 expand §Clinical significance
  80. 08:22, 20 Mar 2025 (diff | hist) Talk:Xi'an Mokemei Biotechnology 959 +255 /* Extract-derived listings need their own treatment */ reply
  81. 16:42, 14 Mar 2025 (diff | hist) SELECT trial 4,206 ±0 state the non-inferiority margin, since the design was non-inferiority
  82. 06:55, 14 Mar 2025 (diff | hist) Reverse-phase HPLC 4,246 ±0 consistent en dashes in ranges
  83. 05:48, 11 Mar 2025 (diff | hist) Multi-dose vial 7,432 +3,066 the example withdrew more than the syringe holds; corrected
  84. 16:06, 10 Mar 2025 (diff | hist) Peptide aggregation 4,041 +13 m add the note on co-elution and what it hides
  85. 20:07, 7 Mar 2025 (diff | hist) Methionine oxidation 3,582 +106 m add short description
  86. 07:54, 1 Mar 2025 (diff | hist) Retatrutide 5,700 ±0 m move the trade-name history out of the lead and into §Regulatory history
  87. 18:00, 25 Feb 2025 (diff | hist) Grey market 2,576 ±0 state the residual-moisture target with the method it is measured by
  88. 19:45, 23 Feb 2025 (diff | hist) Contraindications of incretin therapy 3,408 +34 m move a stray full stop inside the reference
  89. 20:06, 19 Feb 2025 (diff | hist) Exenatide 4,288 +869 add category for the drug class
  90. 21:25, 18 Feb 2025 (diff | hist) International nonproprietary name 3,145 +356 m expand §Relationship to trade and chemical names
  91. 17:34, 13 Feb 2025 (diff | hist) Vial 17,729 +597 m give the vial sizes in millilitres of nominal capacity
  92. 08:03, 12 Feb 2025 (diff | hist) Blind sampling 5,650 +676 m add the retest interval and what triggers one
  93. 13:24, 7 Feb 2025 (diff | hist) Proglucagon 4,998 ±0 expand §Gene and transcript
  94. 08:20, 7 Feb 2025 (diff | hist) Missed dose 4,123 +736 rm the individualised advice — the article describes, it does not instruct
  95. 04:31, 5 Feb 2025 (diff | hist) Drug master file 2,265 +37 m add the effective date to the regulatory table
  96. 22:32, 24 Jan 2025 (diff | hist) Shanghai Wibson Biotechnology 2,202 +441 add the research-use-only statement to the lead rather than only the footer
  97. 08:41, 23 Jan 2025 (diff | hist) Talk:Bachem Holding (Suzhou) 959 +194 /* Purity without a reference standard */ reply
  98. 17:13, 20 Jan 2025 (diff | hist) Peptide supply chain 4,176 +33 correct the freezer temperature range given for long-term storage
  99. 22:05, 18 Jan 2025 (diff | hist) Survodutide 3,973 +648 the half-life in the lead was the terminal figure; label it as such
  100. 13:05, 18 Jan 2025 (diff | hist) Peptide aggregation 3,115 ±0 state that ultraviolet response is not uniform across impurities